Brenda Finucane

Brenda Finucane

Auto-generated profile, based on publicly available information

Brenda Finucane

Department of Developmental Medicine Geisinger Lewisburg Pennsylvania USA

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
30 July 2014 in Journal of Neurodevelopmental Disorders
Verified
Journal Article
Open access
PDF file
CYCarolyn Yrigollen
Carolyn Yrigollen
LMLoreto Martorell
Loreto Martorell
BDBlythe Durbin-Johnson
Blythe Durbin-Johnson
MNMontserrat Naudo
Montserrat Naudo
JGJordi Genoves
Jordi Genoves
FTFlora Tassone
Flora Tassone
The presence of AGG interruptions in the CGG repeat locus of the fragile X mental retardation 1 (FMR1) gene decreases the instability of the allele during transmission from parent to child, and decreases the risk of expansion of a premutation allele to a full mutation allele (the predominant cause of fragile X syndrome) during maternal transmission.

1 June 2021 in Current Opinion in Genetics & Development
Verified
Journal Article
Open access
BFBrenda M Finucane
Brenda M Finucane
DLDavid H Ledbetter
David H Ledbetter
JVJacob Vorstman
Jacob Vorstman
Advances in laboratory testing have significantly increased the detection of rare genetic etiologies of neurodevelopmental psychiatric disorders (NPD), particularly developmental delay/ intellectual disability, autism spectrum disorder, and schizophrenia. Establishing a genetic diagnosis has important medical and personal utility for individuals with these conditions. Diagnostic genetic tests for NPD are clinically available but underutilized outside of medical genetics settings. Without clear multidisciplinary consensus recommendations, active involvement of medical specialists working with NPD patients, and practical education and training, the implementation of genetic testing for NPD will continue to lag behind other areas of medicine. In the long-term, collaborative efforts to address educational, logistical, and workforce obstacles will improve patient care and pave the way for targeted, effective NPD treatments.

1 April 2016 in Genetics in Medicine
Verified
Journal Article
Open access
BFBrenda Finucane
Brenda Finucane
TCThomas D. Challman
Thomas D. Challman
CMChrista Lese Martin
Christa Lese Martin
DLDavid H. Ledbetter
David H. Ledbetter

15 October 2024 in Nature Communications
Verified
Journal Article
Open access
PDF file
ABAlexander S. F. Berry
Alexander S. F. Berry
BFBrenda M. Finucane
Brenda M. Finucane
SMScott M. Myers
Scott M. Myers
LWLauren K. Walsh
Lauren K. Walsh
JSJohn M. Seibert
John M. Seibert
MOMatthew T. Oetjens
Matthew T. Oetjens
A female protective effect has long been postulated as the primary explanation for the four-fold increase of autism spectrum disorder (ASD) diagnoses in males versus females. However, genetic and epidemiological investigations of this hypothesis have so far failed to explain the large difference in ASD prevalence between the sexes. To address this knowledge gap, we examined sex chromosome aneuploidy in a large ASD case-control cohort to evaluate the relationship between X and Y chromosome dosage and ASD risk. From these data, we modeled three relationships between sex chromosome dosage and ASD risk: the extra Y effect, the extra X effect, and sex chromosome haploinsufficiency. We found that the extra Y effect increased ASD risk significantly more than the extra X effect. Among females, we observed a large association between 45, X and ASD, confirming sex chromosome haploinsufficiency as a strong ASD risk factor. These results provide a framework for understanding the relationship between X and Y chromosome dosage on ASD, which may inform future research investigating genomic contributors to the observed sex difference.

13 June 2020 in Current Opinion in Genetics & Development
Verified
Journal Article
Open access
BFBrenda M Finucane
Brenda M Finucane
SMScott M Myers
Scott M Myers
CMChrista L Martin
Christa L Martin
DLDavid H Ledbetter
David H Ledbetter
Developmental brain disorders (DBD), including autism spectrum disorder, intellectual disability, and schizophrenia, are clinically defined and etiologically heterogeneous conditions with a wide range of outcomes. Rare pathogenic copy number and single nucleotide genomic variants are among the most common known etiologies, with diagnostic yields approaching for some DBD cohorts. Incorporating genetic testing into the care of adult patients with DBD, paired with targeted genetic counseling and family cascade testing, may increase self-advocacy and decrease stigma. In the long-term, breakthroughs in the understanding of DBD pathophysiology will hinge on the identification, engagement, and study of individuals with rare genetic DBD etiologies, consistent with successful precision medicine approaches to the treatment of cancer and cardiovascular disease.

24 June 2016 in Current Genetic Medicine Reports
Verified
Journal Article
Open access
PDF file
BFBrenda Finucane
Brenda Finucane
SMScott M. Myers
Scott M. Myers
Purpose of Review Psychiatry is steadily moving toward a new conceptualization of brain disorders that blurs long-held diagnostic distinctions among neurodevelopmental and psychiatric conditions, including autism. Genomic discoveries are driving these changing perceptions, yet there has so far been minimal impact on traditional genetic counseling practices that continue to view autism through the lens of a dichotomous, all-or-none risk model. Recent Findings High rates of comorbidity exist across autism spectrum disorder, schizophrenia, intellectual disability, and other brain-based disorders. Recent epidemiological studies have shown that co-occurrence of neurodevelopmental and psychiatric disorders is the rule, rather than the exception, in affected individuals and within families. Moreover, studies of chromosomal microarray analysis and whole exome sequencing have now detected many of the same pathogenic copy number and sequence-level variants across cohorts with different clinical presentations. Summary Going forward, the genetic counseling field will need to significantly adapt its approaches to pedigree interpretation, variant analysis, and patient education to more precisely describe both the chance and the nature of autism recurrence in terms of a continuum of brain dysfunction. These efforts will have implications for multiple practice areas and require philosophical changes for experienced practitioners and for the training of new genetic counselors. Resetting entrenched dichotomous notions about autism and other brain-based manifestations of genetic conditions will require a strategic educational effort on the part of the genetic counseling profession.